Investing.com -- Novartis (SIX: NOVN ) announced Thursday that its Cosentyx drug did not meet its primary goal in a Phase III trial for adults with giant cell arteritis (GCA).

The drug failed to demonstrate an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, according to the Swiss pharmaceutical company.

Shreeram Aradhye, president of development and chief medical officer at Novartis, said: "While the Phase III results did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.